Pokey, it sure looks like it is a continuation of
Post# of 36537
(Total Views: 222)
Posted On: 04/20/2020 10:25:39 AM
Pokey, it sure looks like it is a continuation of Dr von Hofe’s explanation. I don’t think a writer will come up with a process themselves.
“It is a two-fold process,” said Eric von Hofe, chief scientific officer of NuGenerex Immuno-Oncology, a subsidiary of Generex. The team will be looking for a T-cell response to these peptides, as well as the generation of antibodies. After starting and completing trials in animal models, Generex hopes to begin clinical trials with about 200 volunteers that will receive the peptide-based vaccine to determine whether this produces the desired immune response and to ensure the safety of the vaccine.
“It is a two-fold process,” said Eric von Hofe, chief scientific officer of NuGenerex Immuno-Oncology, a subsidiary of Generex. The team will be looking for a T-cell response to these peptides, as well as the generation of antibodies. After starting and completing trials in animal models, Generex hopes to begin clinical trials with about 200 volunteers that will receive the peptide-based vaccine to determine whether this produces the desired immune response and to ensure the safety of the vaccine.
(0)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.
Scroll down for more posts ▼